151. Influence of captopril on cis-diamminedichloroplatinum-induced renal toxicity
- Author
-
Sytze Meijer, Nanno Mulder, Dirk Sleijfer, Gk Vanderhem, Hs Koops, Ajm Donker, and Jjg Offerman
- Subjects
Adult ,Male ,medicine.medical_specialty ,Captopril ,medicine.medical_treatment ,Urology ,Renal function ,urologic and male genital diseases ,Kidney ,Nephrotoxicity ,Nephropathy ,Renal Circulation ,Testicular Neoplasms ,Internal medicine ,medicine ,Humans ,Testicular cancer ,Chemotherapy ,Clinical Trials as Topic ,business.industry ,Effective renal plasma flow ,Middle Aged ,medicine.disease ,Endocrinology ,Nephrology ,Toxicity ,Cisplatin ,business ,medicine.drug ,Glomerular Filtration Rate - Abstract
Renal function studies were performed in 18 patients with nonseminomatous testicular cancer during four platinum-containing chemotherapy courses. The first 9 patients received chemotherapy alone, the second 9 also captopril, an angiotensin I converting enzyme inhibitor, in order to prevent cis-diamminedichloroplatinum-induced nephrotoxicity. In the first group a decrease in glomerular filtration rate, that was preceded by a fall in effective renal plasma flow, was observed. In the second group, captopril was able to prevent the initial decrease in effective renal plasma flow, but failed to prevent the ultimate decrease in glomerular filtration rate.
- Published
- 1985